Skip to content
DataLookout
Menu

NCT07930182

Adjuvant/Neoadjuvant Immunotherapy in Melanoma Based on Serial Plasma ctDNA Monitoring

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Event-Free Survival (EFS) in the Neoadjuvant Cohort
Timeframe: Up to 5 Years
Relapse-Free Survival (RFS) in the Adjuvant Cohort
Timeframe: Up to 5 years

Secondary (3)

Pathologic Response Rate (Neoadjuvant Cohort)
Objective Response Rate (ORR) by RECIST v1.1 (Neoadjuvant Cohort)
Relapse With Undetectable ctDNA

Arms and interventions

Neoadjuvant cohortExperimental

Patients with resectable stage III/IV melanoma eligible for neoadjuvant treatment will be enrolled. Patient cases will be reviewed with the surgery team to confirm surgical resectability prior to enrollment and CT imaging will be obtained at baseline, as per standard of care.

Adjuvant cohortExperimental

Patients who already underwent complete surgical resection of stage IIB/IIC/III/IV melanoma (and did not receive prior neoadjuvant treatment.) All patients in this cohort must be within 10 weeks of surgery and have CT scans post-surgery prior to study enrollment to confirm they are radiographically disease-free. Following study enrollment, all patients will have the first ctDNA analyses done within 12 weeks of date of surgery.

Drugs: Nivolumab, Ipilimumab

Diagnostic tests: Haystack MRD ctDNA Assay

Sites

1 site in 1 country

  • Moffitt Cancer CenterTampa, Florida, United States